Inhibitors of advanced glycation end product-associated protein cross-linking

被引:33
作者
Lehman, TD [1 ]
Ortwerth, BJ [1 ]
机构
[1] Univ Missouri, Sch Med, Mason Eye Inst, Columbia, MO 65212 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2001年 / 1535卷 / 02期
关键词
glycation; protein cross-linking; L-threose; advanced glycation end product; cataract; reducing agent; 2-aminoguanidine; metabisulfite;
D O I
10.1016/S0925-4439(00)00087-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The reaction of lens proteins with sugars over time results in the formation of protein-bound advanced glycation end products (AGEs). The most damaging element of AGE formation may be the synthesis of protein-protein cross-links in long-lived proteins, such as collagen or lens crystallins. A quantitative cross-linking assay, involving the sugar-dependent incorporation of [U-C-14]lysine into protein, was employed to determine the efficacy of a variety of potential cross-linking inhibitors. Reaction mixtures contained 5.0 mM L-threose, 2.5 mu Ci [C-14]lysine (1.0 mCi/mmole), 5.0 mg/ml bovine lens proteins, 0-10 mM inhibitor and 1.0 mM DTPA in 100 mM phosphate buffer, pH 7.0. Of 17 potential inhibitors tested, 11 showed 50% inhibition or less at 10 mM. The dicarbonyl-reactive compounds 2-aminoguanidine, semicarbazide and o-phenylenediamine inhibited 50% at 2.0 mM, whereas 10 mM dimethylguanidine had no effect. Several amino acids failed to compete effectively with [C-14]lysine in the cross-linking assay; however, cysteine inhibited 50% at 1.0 mM, This was likely due to the sulfhydryl group of cysteine, because 3-mercaptopropionic acid and reduced glutathione exhibited similar activity. Sodium metabisulfite had the highest activity, inhibiting 50% at only 0.1-0.2 mM. Protein dimer formation, as determined by SDS-PAGE, was inhibited in a quantitatively similar manner. The dicarbonyl-reactive inhibitors and the sulfur-containing compounds produced similar inhibition curves for [C-14]lysine incorporation over a 3 week assay with 250 mM glucose. A much lesser effect was observed on either the incorporation of [C-14]glucose, or on fluorophore formation (360/420 nm), suggesting that non-cross-link fluorophores were also formed. The inhibitor data were consistent with cross-linking by a dicarbonyl intermediate. This was supported by the fact that the inhibitors were uniformly less effective when the 5.0 mM threose was replaced by either 3.0 mM 3-deoxythreosone or 3.0 mM threosone. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:110 / 119
页数:10
相关论文
共 46 条
  • [1] BAYNES JW, 1984, METHOD ENZYMOL, V106, P88
  • [2] Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanidine
    Booth, AA
    Khalifah, RG
    Hudson, BG
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 220 (01) : 113 - 119
  • [3] Advanced glycosylation end products in diabetic renal and vascular disease
    Bucala, R
    Vlassara, H
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (06) : 875 - 888
  • [4] Preventive aspirin treatment of streptozotocin induced diabetes: blockage of oxidative status and revertion of heme enzymes inhibition
    Caballero, F
    Gerez, E
    Batlle, A
    Vazquez, E
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2000, 126 (03) : 215 - 225
  • [5] CAMERON NE, 1995, N-S ARCH PHARMACOL, V352, P685
  • [6] POLYMERIZATION OF ACETYLATED LYSOZYME AND IMPAIRMENT OF THEIR AMINO-ACID-RESIDUES DUE TO ALPHA-DICARBONYL AND ALPHA-HYDROXYCARBONYL COMPOUNDS
    CHO, RK
    OKITANI, A
    KATO, H
    [J]. AGRICULTURAL AND BIOLOGICAL CHEMISTRY, 1986, 50 (06): : 1373 - 1380
  • [7] Antioxidant properties of aminoguanidine
    Courderot-Masuyer, C
    Dalloz, F
    Maupoil, V
    Rochette, L
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (05) : 535 - 540
  • [8] Prevention of lens protein glycation by taurine
    Devamanoharan, PS
    Ali, AH
    Varma, SD
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 1997, 177 (1-2) : 245 - 250
  • [9] MECHANISTIC STUDIES OF ADVANCED GLYCOSYLATION END-PRODUCT INHIBITION BY AMINOGUANIDINE
    EDELSTEIN, D
    BROWNLEE, M
    [J]. DIABETES, 1992, 41 (01) : 26 - 29
  • [10] Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)
    Freedman, BI
    Wuerth, JP
    Cartwright, K
    Bain, RP
    Dippe, S
    Hershon, K
    Mooradian, AD
    Spinowitz, BS
    [J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (05): : 493 - 510